5 Biotech Stocks That Returned Triple Digit Gains

La Jolla Pharmaceutical
La Jolla Pharmaceutical

We alerted LJPC to our subscribers on January 3, 2017 when it was trading around $17.64. Our report on La Jolla titled “What Are The Odds – Low or High?” dwelled on LJPC-501, the now approved Giapreza.

Giapreza was approved by the FDA on December 21, 2017 for the treatment of hypotension in adults with septic or other distributive shock.

Septic or other distributive shock is a critical condition in which blood pressure drops so low that the brain, kidneys and other vital organs can't receive enough blood flow to function properly. Giapreza effectively increases blood pressure when added to conventional treatments used to raise blood pressure.

The drug is expected to be launched in the U.S. in March 2018.

On March 20, 2017, LJPC had touched a high of $39.28, and that represents a gain of nearly 122% in 3.5 months from our published price. The stock closed Tuesday’s (Dec.26) trading at $32.79, up 4.26%.